7-fluoro-5H-imidazo[2,1-a]isoindole-2-carbaldehyde | 1376769-10-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 7-fluoro-5H-imidazo[2,1-a]isoindole-2-carbaldehyde
• CAS: 1376769-10-6
• 化学式: C₁₁H₇FN₂O
• 分子量: 202.188
• InChiKey: PGJUNPGKEFXHFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Imidazole derivatives as PDE10A enzyme inhibitors
  申请人：Kehler Jan

  公开号：US20120129836A1

  公开（公告）日：2012-05-24

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  这项发明涉及一类PDE10A酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用载体的药物组合物。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗神经退行性疾病的方法，包括向患有神经退行性疾病的受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗药物成瘾的方法，包括向患有药物成瘾的受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗精神障碍的方法，包括向患有精神障碍的受试者施用式I化合物的治疗有效量。
• [EN] QUINAZOLINE LINKED HETEROAROMATIC TRICYCLE DERIVATIVES AS PDE10A ENZYME INHIBITORS<br/>[FR] DÉRIVÉS TRICYCLIQUES HÉTÉROAROMATIQUES LIÉS À DE LA QUINAZOLINE POUVANT ÊTRE UTILISÉS EN TANT QU'INHIBITEURS DE L'ENZYME PDE10A
  申请人：LUNDBECK & CO AS H

  公开号：WO2013045607A1

  公开（公告）日：2013-04-04

  This invention is directed to compounds of formula I which are PDE10A enzyme inhibitors, pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier and processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder, a drug addiction or a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. Formula I, wherein Q is selected from the group consisting of (Q1), (Q2), (Q3), (Q4), and (Q5).

  这项发明涉及公式I的化合物，这些化合物是PDE10A酶抑制剂，包括发明化合物的治疗有效量和药用载体的药物组合物，以及公式I化合物的制备方法。本发明进一步提供了一种治疗患有神经退行性疾病、药物成瘾或精神障碍的受试者的方法，包括向受试者投予公式I化合物的治疗有效量。公式I中，Q从（Q1）、（Q2）、（Q3）、（Q4）和（Q5）组成的群中选择。
• Tricyclic imidazole compounds as PDE10 inhibitors
  申请人：H. Lundbeck A/S

  公开号：US20140005201A1

  公开（公告）日：2014-01-02

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  该发明涉及一种PDE10A酶抑制剂化合物。该发明提供了一种药物组合物，包括一种该发明化合物的治疗有效量和药物可接受载体。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗神经退行性疾病患者的方法，包括向患者施用式I化合物的治疗有效量。本发明还提供了一种治疗药物成瘾患者的方法，包括向患者施用式I化合物的治疗有效量。本发明还提供了一种治疗精神障碍患者的方法，包括向患者施用式I化合物的治疗有效量。
• Imidazole derivatives as PDE10 enzyme inhibitors
  申请人：H. Lundbeck A/S

  公开号：US20140357639A1

  公开（公告）日：2014-12-04

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  本发明涉及一种PDE10A酶抑制剂化合物。该发明提供了一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明还提供了制备公式I化合物的方法。本发明还提供了一种治疗神经退行性疾病的方法，包括向患者施用公式I化合物的治疗有效量。本发明还提供了一种治疗药物成瘾的方法，包括向患者施用公式I化合物的治疗有效量。本发明还提供了一种治疗精神疾病的方法，包括向患者施用公式I化合物的治疗有效量。
• IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS
  申请人：H. Lundbeck A/S

  公开号：EP2640731A1

  公开（公告）日：2013-09-25